Figure B.4.
MLL‐rearranged acute lymphoblastic leukaemias activate BCL‐2 through H3K79 methylation and are sensitive to the BCL‐2‐specific antagonist ABT‐199 (Benito et al., 2015, CC‐BY)
MLL‐rearranged acute lymphoblastic leukaemias activate BCL‐2 through H3K79 methylation and are sensitive to the BCL‐2‐specific antagonist ABT‐199 (Benito et al., 2015, CC‐BY)